莫西沙星联合头孢哌酮钠舒巴坦钠治疗老年重症肺炎的临床研究  

Clinical study of moxifloxacin combined with cefoperazone sodium and sulbactam sodium in the treatment of elderly patients with severe pneumonia

作　　者：赵红伟 ZHAO Hong-wei(Cadre Ward,General Hospital of the Northern Theater Command of the Chinese People's Liberation Army,Shenyang 110000,China)

机构地区：[1]中国人民解放军北部战区总医院干诊科,110000

出　　处：《中国现代药物应用》2023年第1期100-102,共3页Chinese Journal of Modern Drug Application

摘　　要：目的 探究老年重症肺炎患者采用莫西沙星联合头孢哌酮钠舒巴坦钠治疗的临床效果。方法 106例老年重症肺炎患者为研究对象,依据随机数字表法分为研究组与对照组,各53例。对照组采用头孢哌酮钠舒巴坦钠治疗,研究组采用莫西沙星联合头孢哌酮钠舒巴坦钠治疗。对比两组治疗效果、症状(咳嗽、发热、胸痛)改善时间、不良反应发生情况。结果 研究组治疗总有效率为94.34%,明显高于对照组的79.25%,差异有统计学意义(P<0.05)。研究组咳嗽消失时间(4.55±1.11)d、退热时间(3.58±1.06)d、胸痛消失时间(4.29±1.38)d均短于对照组的(5.16±1.19)、(4.26±1.22)、(5.17±1.64)d,差异均有统计学意义(P<0.05)。研究组不良反应发生率为7.55%,与对照组的5.66%对比,差异无统计学意义(P>0.05)。结论 莫西沙星联合头孢哌酮钠舒巴坦钠治疗老年重症肺炎效果突出,可缩短症状改善时间,值得临床推广应用。Objective To investigate the clinical effect of moxifloxacin combined with cefoperazone sodium and sulbactam sodium in the treatment of elderly patients with severe pneumonia. Methods A total of 106 elderly patients with severe pneumonia were randomly divided into research group and control group according to random numerical table, with 53 cases in each group. The control group was treated with cefoperazone sodium and sulbactam sodium, while the research group was treated with moxifloxacin in combination with cefoperazone sodium and sulbactam sodium. The therapeutic effect, improvement time of symptoms(cough, fever, chest pain),and occurrence of adverse reactions of the two groups were compared. Results The total effective rate of the research group was 94.34%, which was significantly higher than 79.25% of the control group, and the difference was statistically significant(P<0.05). The disappearance time of cough(4.55±1.11) d, disappearance time of fever(3.58±1.06) d and disappearance time of chest pain(4.29±1.38) d in the research group were shorter than(5.16±1.19),(4.26±1.22) and(5.17±1.64) d in the control group, and the differences were statistically significant(P<0.05). The incidence of adverse reactions in the research group was 7.55%, which had no statistically significant difference compared with 5.66% in the control group(P>0.05). Conclusion Moxifloxacin combined with cefoperazone sodium and sulbactam sodium in the treatment of elderly patients with severe pneumonia is effective, and the symptom improvement time is short, which is worthy of clinical popularization and application.

关 键 词：莫西沙星 头孢哌酮钠舒巴坦钠 老年重症肺炎 

分 类 号：R563.1[医药卫生—呼吸系统]